The study demonstrates that TLR4 mediates the rapid uptake of fetuin‐A by tumor cells to promote rapid adhesion, spreading, growth, motility, and invasion in serum‐free medium. The specific TLR4 inhibitor, CLI‐095, inhibits rapid fetuin‐A uptake, and consequently, most tumor cells, particularly those that do not synthesize fetuin‐A, fail to adhere, spread, or grow in serum‐free medium.